$ATRA News

Atara Biotherapeutics Q1 EPS $(0.29) Beats $(0.41) Estimate, Sales $516.000K Miss $2.850M Estimate

Atara Biotherapeutics Files Prospectus For Offering $79.3M Common Shares

FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate)

Canaccord Genuity Upgrades Atara Biotherapeutics to Buy, Raises Price Target to $13

Atara Biotherapeutics Issues Update Following Recent Type A Meeting With FDA To Discuss CRL To BLA For Tabelecleucel Held By Its Partner Pierre Fabre Pharma

Atara Biotherapeutics shares are trading lower after the company reported worse-than-expected Q4 sales results.

Atara Biotherapeutics shares are trading lower after the company reported worse-than-expected Q4 sales results.

Atara Biotherapeutics Q4 EPS $(0.25) Beats $(0.44) Estimate, Sales $1.595M Miss $2.671M Estimate

The FDA Has Scheduled Type A Meeting To Discuss The Complete Response Letter To Atara Biotherapeutics' Biologics License Application For Tabelecleucel (Tab-cel) Held By Partner Pierre Fabre Pharmaceuticals

Top stock movements in today's session.

Gapping stocks in Monday's session

12 Health Care Stocks Moving In Monday's Pre-Market Session

Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Atara Biotherapeutics shares are trading higher after the company announced its partner Pierre Fabre Pharmaceuticals has submitted a request to the FDA for a Type A meeting on ALLELE trial.

Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Submits Request To FDA For Type A Meeting About ALLELE Trial

'A Rare Disease Drug Was Approvable, Then It Wasn't. Inside A Surprise Rejection By The FDA; Drugmakers Say Agency's Reasons For Decision Were At Odds With Previous Exchanges' - STAT News

Atara's Outlook As Ebvallo Hits Second FDA CRL

Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6

FDA Rejects Atara Biotherapeutics' Cell Therapy Again, Stock Sinks

Atara Biotherapeutics shares are trading lower after the company announced it received a Complete Response Letter from the FDA stating that the Agency is unable to approve the tabelecleucel Biologics License Application in its present form.